Relapse and rehospitalisation rates in patients with schizophrenia: Effects of second generation antipsychotics

CNS Drugs

Volumn 16, Issue 7, 2002, Pages 473-484

  Csernansky, John G ^a   Schuchart, Emily K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; DOSE CALCULATION; DRUG EFFICACY; DRUG FORMULATION; FOLLOW UP; HEALTH; HEALTH CARE COST; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; METABOLIC DISORDER; NEUROLOGIC DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEX DIFFERENCE; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0036307453     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216070-00004     Document Type: Review

References (74)

1. Symptoms of schizophrenia: Methods, meanings and mechanisms
2. What are the consequences of neurocognitive deficits in schizophrenia?
3. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
4. Cost of relapse in schizophrenia
5. Predictors of relapse and rehospitalisation in schizophrenia and schizoaffective disorder
6. Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders
7. Psychiatric and social reasons for frequent hospitalization
8. Identifying modifiable risk factors for rehospitalisation: A case-control study of seriously mentally ill persons in Mississippi
9. Predicting medication noncompliance after hospital discharge among patients with schizophrenia
10. Assessing clinical predictions of early rehospitalisation in schizophrenia
11. Gender differences in schizophrenia: Rehospitalisation and community survival
12. Predictability of rehospitalisation for schizophrenia
13. Quality of life and clinical predictors of rehospitalisation of persons with severe mental illness
14. Rehospitalisation in chronic schizophrenia
15. Risk of rehospitalisation of psychotic patients: A 6-year follow-up investigation using the survival approach
16. Maintenance therapy and the natural course of schizophrenia
17. Maintenance pharmacotherapy in schizophrenia
18. Relapse and rehospitalisation during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment
19. Maintenance medication for schizophrenia: Strategies for dose reduction
20. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia
21. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates
22. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome
23. A one-year comparison of four dosages of haloperidol decanoate
24. Positron emission tomographic analysis of central dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
25. Drug refusal in schizophrenia and the wish to be crazy
26. Why do schizophrenic patients refuse to take their drugs?
27. Risperidone in the treatment of schizophrenia
28. Clozapine for the treatment-resistant schizo-phrenic: A double-blind comparison with chlorpromazine
29. Clozapine in schizophrenic outpatients: Efficacy, long-term outcome, and relationship to prefrontal cortex
30. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
31. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia
32. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia
33. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample
34. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
35. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications
36. Effectiveness of clozapine and olanzapine: A comparison in severe, psychotically ill patients
37. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
38. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multi-center double-blind comparative study
39. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
40. A multicentre, doubleblind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
41. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studies
42. Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia
43. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo: The Seroquel Trial 13 Study Group
44. Ziprasidone: Comprehensive overview and clinical use of a novel antipsychotic
45. Adherence to antipsychotic medications
46. Tolerability of atypical antipsychotics
47. Neuroleptic-induced akathisia: A review
48. Clinical characteristics of akathisia
49. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment
50. Correlations between akathisia and residual psychopathology: A by-product of neuroleptic-induced dysphoria
51. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients
52. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance
53. Subjective response as a predictor of outcome in pharmacotherapy
54. Practice guidelines for the treatment of patients with schizophrenia
55. Randomised doubleblind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
56. Antipsychotic-induced weight gain: A comprehensive research synthesis
57. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities
58. Novel antipsychotics and new onset diabetes
59. Risperidone-associated new-onset diabetes
60. Patients' opinions concerning side effects of depot neuroleptics
61. Review of atypical antipsychotics and weight gain
62. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
63. Suicide attempts associated with akathisia
64. Violence as a manifestation of akathisia
65. Appraisal of the 'tranquilizers' and their influence on other somatic treatments in psychiatry
66. Schizophrenia costs and treatment cost-effectiveness
67. Partial versus full hospitalization for adults in psychiatric distress: A systematic review of the published literature (1957-1997)
68. A two-year clinical and economic follow-up of patients on clozapine
69. Rehospitalisation rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics
70. Rehospitalisation rates of patients recently discharged on a regimen of risperidone or clozapine
71. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
72. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia
73. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia
74. Rehospitalisation rates for depot antipsychotics and pharmacoeconomic implications: Comparison with risperidone